Immune aspects of TTP study
Part of Blood & lymphatic clinical trials.
This trial is looking at the immune system's role in thrombotic thrombocytopenic purpura (TTP), a rare blood disorder. It may help researchers understand the condition better and possibly improve future treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- You must have a diagnosis of thrombotic thrombocytopenic purpura (TTP) at any stage: acute, in remission, or relapsed.
- You must receive care at the internal medicine department of Rouen University Hospital.
- You must have read and understood the information letter about the study.
- You must have a valid social security registration.
- You cannot be under any form of legal restriction or guardianship.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks back at medical records of people with immune-mediated thrombotic thrombocytopenic purpura (TTP), a rare blood clotting disorder. It aims to better understand the disease and how it is treated.
This study looks at how patients with a rare blood disorder called congenital thrombotic thrombocytopenic purpura (cTTP) are doing while being treated with a replacement therapy called recombinant ADAMTS13. It aims to understand real-world experiences and outcomes.
This study looks back at medical records of people with a rare blood disorder called congenital thrombotic thrombocytopenic purpura (cTTP) who received a treatment called recombinant ADAMTS13 (rADAMTS13). The goal is to learn more about how this treatment works in real life.
This study is testing a new combination of medicines—immune-suppressing drugs, caplacizumab, and plasma infusions—to treat immune-mediated TTP without standard plasma exchange. It aims to make treatment simpler and potentially safer.
This study is a national registry that collects medical information from people diagnosed with a type of blood-clotting disorder called acquired TTP (aTTP). It may help researchers better understand the disease and how it’s managed, without necessarily changing your treatment.
This is a real-world registry that collects information about people diagnosed with thrombotic thrombocytopenic purpura (TTP) in Spain and Portugal. It helps researchers understand TTP patterns and outcomes, and participation is voluntary.
Hear when a new Thrombotic Thrombocytopenic Purpura (TTP) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.